Jinwon Life Sciences Subsidiary VGXI Forms Strategic Partnership with Sutro Biopharma
Jinwon Life Sciences announced on the 4th that its subsidiary VGXI, a leading contract development and manufacturing organization (CDMO) in the field of nucleic acid biopharmaceuticals such as gene therapy, DNA vaccines, and RNA drugs, has formed a strategic partnership with Nasdaq-listed Sutro Biopharma, Inc. VGXI will be responsible for producing plasmid DNA used in clinical trials of luveltamab tazevibulin (luvelta), an antibody-drug conjugate (ADC) anticancer agent developed by Sutro Biopharma.
Sutro Biopharma, a clinical-stage ADC anticancer drug developer targeting ovarian cancer, recently initiated Part 2 studies for the global Phase 2/3 clinical trial of luvelta. VGXI will produce and supply the plasmid DNA required for Sutro Biopharma’s XpressCF cell-free expression system for luvelta manufacturing using a 1500L fermenter.
Youngkeun Park, CEO of Jinwon Life Sciences, said, “We are pleased to establish a strategic partnership to support not only the clinical production of luvelta but also all ongoing projects of Sutro Biopharma. Our company’s expertise and technology in large-scale plasmid DNA production will play a crucial role in advancing and commercializing Sutro Biopharma’s promising therapeutics in late-stage clinical development.”
Hot Picks Today
"King crab is 3,000 won per 500 grams; just eating it makes the trip worthwhile"... Chinese flock to North Korea on 'fake business trips'
- "I Thought Only Samsung and SK Were Thriving"... Chinese Chipmaker Forecasts 600% Revenue Surge
- "A Mourning Run? That's Disturbing": Posting Running Records to Honor Deceased Runner... Some Call It "A Runner's Way"
- "I Ate It Often Because It Tasted Good"... This Eating Habit Linked to 40% Higher Odds of Asymptomatic Cerebrovascular Damage
- "Why on earth come to Korea and do this?" ... Chinese Man in Hanfu Says He'll Promote Chinese Culture at Gyeongbokgung
Dr. Venkatesh Srinivasan, Chief Technology and Operations Officer of Sutro Biopharma, stated, “The partnership with VGXI has laid the foundation for further activating the cell-free manufacturing platform at a commercial scale as leading drug candidates progress into clinical development.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
!["Please Take Them Off!" They Made It All the Way to the Bed... Then "80% of Fecal Bacteria" Struck [Deep Scroll]](https://cwcontent.asiae.co.kr/asiaresize/307/2026101610053063338_1792112730.png)
